CD274 and neoplasm: The IMpower010 phase III adjuvant immunotherapy study (24) revealed that atezolizumab, administered after adjuvant platinum-based chemotherapy in patients with early-stage NSCLC, significantly enhanced DFS in stage II–IIIA NSCLC patients with PD-L1 expression levels ≥1% on tumor cells, in comparison to best supportive care (HR, 0.66, P = 0.0039).